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Designed supramolecular filamentous peptides:
balance of nanostructure, cytotoxicity and
antimicrobial activity†
Dawei Xu,‡a Linhai Jiang,‡a Anju Singh,b Derek Dustin,a Miao Yang,a Ling Liu,c
Reidar Lund,d Timothy J. Sellatib and He Dong*a
This work demonstrates a design strategy to optimize antimicrobial
peptides with an ideal balance of minimal cytotoxicity, enhanced
stability, potent cell penetration and effective antimicrobial activity,
which hold great promise for the treatment of intracellular microbial
infections and potentially systemic anti-infective therapy.
Naturally occurring antimicrobial peptides (AMPs) serve as the first
line of host defense against a variety of microbial infections.1 A large
number of AMPs consisting of both natural and non-natural amino
acids have been de novo designed.2 In the past, the majority of work
has focused on sequence variation and structural optimization of
single peptide chains to achieve a balance between antimicrobial
efficiency and selectivity. Successful design has and will continue to
advance topical application of AMPs in clinically relevant settings.
However, for systemic antimicrobial therapy using AMPs, parti-
cularly for the targeting of intracellular microbial pathogens, new
strategies are highly desirable to overcome the intrinsic limitations
associated with single peptide chains. Such limitations include
cytotoxicity, protease susceptibility (for a-peptides), poor cell pene-
tration activity, and limited in vivo circulation half-life.
Peptide-based supramolecular assemblies represent an emer-
ging and important class of biomaterials that have been extensively
utilized in various biomedical fields, including drug delivery,3
vaccination,4 3-D cellular scaffolds,5 and antimicrobial hydrogels.6
Supramolecular peptides are assemblies of monomeric peptides
held together by non-covalent interactions to form discrete nano-
structures or nanostructured networks. Compared to single peptide
chains, these large-scale assemblies have a distinctive mode of
cellular interactions which can be tuned by adjusting peptide
primary sequences and thus the intermolecular interactions
between individual peptide chains. For example, the Stupp group
has recently discovered that the supramolecular cohesion force in
selected peptide amphiphiles has significant effects on cytotoxicity
toward mammalian cell lines.7 Our group reported on the cell
penetration activity of two cationic peptides which differ in
their ability to self-assemble into supramolecular nanofibers.3a
Nanofiber-forming peptides showed dramatically enhanced cell
uptake compared to monomeric peptides. We have also observed
dramatically different cytotoxicity profiles for fibrous peptides
versus peptide monomers. Based on these preliminary results, we
started to systematically evaluate the cytotoxicity, protease stability,
and antimicrobial activity of these supramolecular peptides. The
progress of this study may potentially lead to supramolecular AMPs
with an ideal balance of minimal cytotoxicity, enhanced stability,
potent cell penetration, and effective antimicrobial activity for the
application of systemic anti-infective treatments.
The peptide sequences are based upon previously designed
multidomain peptides (MDPs) with a general formula of
Kx(QL)yKz, which are cationic as well as amphiphilic.
8 Unlike
most AMPs that exist as a monomer prior to their binding with
lipid membranes, MDPs can be formulated into soluble supra-
molecular nanofibers. The supramolecular nanostructure and
stability can be tuned by adjusting the ratio between different
blocks. The end products reflect an energetic balance between
the intermolecular hydrogen bonding and hydrophobic inter-
actions among the (QL) repeating units and electrostatic repul-
sion among the lysine residues. Scheme 1 shows a representative
chemical structure of a MDP and its self-assembly into supra-
molecular nanofibers.
Three peptides were used in the current study, MDP-1
(WK2(QL)6K2), 2 (WK3(QL)6K2), and 3 (K3W(QL)6K2), which are
designed to form supramolecular assemblies above a critical
assembly concentration (CAC). For all the peptides, tryptophan
(W) was incorporated for accurate concentration measurement.
The position of W was also found to influence the molecular
secondary structure, supramolecular nanostructure, stability,
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and the antimicrobial activity of MDP-2 and MDP-3, which have
identical amino acid compositions.
Fig. S1 (ESI†) shows the circular dichroism (CD) spectra of all
three peptides. The secondary structure of WK2(QL)6K2 (MDP-1)
showed predominantly beta sheets as characterized by a single
minimum peak at 216 nm. Adding an additional lysine residue
led to denaturation of ordered beta sheets into random coils
more likely at both termini. For WK3(QL)6K2 (MDP-2), fitting of
the CD spectrum gives rise to 41.4% beta sheets, 40% random
coils and the rest being alpha helices. However, for K3W(QL)6K2
(MDP-3) with the same number of lysine residues as WK3(QL)6K2,
switching the three N-terminal lysine residues with W led to a
restoration of beta sheet structure. This is largely due to the
creation of the additional ‘‘KW’’ hydrophobic–hydrophilic repeat-
ing unit following the (QL)6 domain at the N terminus so as to
increase the driving force for beta sheet formation.
As shown in Fig. 1, all three peptides are capable of self-
assembling into supramolecular nanofibers above their CACs.
The CAC was determined by the previously established fluores-
cence self-quenching method where the fluorescence intensity
of fluorescein labeled peptides was measured as a function of
peptide concentration.9 Due to the formation of supramolecular
assemblies, the fluorophores are in spatial proximity such that
the change of the fluorescence intensity falls off the linear range
and the cross point between the two regions is defined as the
CAC. The CACs for MDP-1, 2, and 3 are 0.87 mM, 1.24 mM and
1.37 mM, respectively (Fig. S2, ESI†).
The nanostructure formation is further confirmed and
quantified in more detail using small-angle X-ray scattering
(SAXS). The data were fitted on an absolute intensity scale using
a form factor of a regular platelet, i.e. long filaments, described
by the three lengths, a o b o c. The SAXS data (Fig. S3, ESI†)
suggest rather well-defined fibers in solution with lengths (c) of
40–50 nm, width (b) of 5.8, 6.7, and 5.7 nm, and height (a) of
4.8, 4.7, and 2.7 nm for WK2(QL)6K2,WK3(QL)6K2 and K3W(QL)6K2,
respectively. The fitting was greatly improved by incorporating a
Gaussian distribution function describing a dispersion in a of
B28%, 35%, and 20% respectively. The difference in the fiber
dimensions was presumably due to the ‘‘edge’’ effect of the
lysine residues adopting different molecular secondary structures.
A non-canonical geometric model and fitting methods will be
developed to elucidate the fine structure and packing of these
nanofibers for future studies.
The cytotoxicity of the three MDPs and melittin, a naturally
occurring AMP, was evaluated using primary mouse bone marrow-
derivedmonocytes (BMDMs). After 24 h of incubation with different
peptides at concentrations of 1, 5, and 20 mM, released lactate
dehydrogenase (LDH), an indicator of cell death, was quantified by
ELISA (Fig. 2a and b). The percent cytotoxicity was calculated relative
to the manufacturer-provided positive cell lysis control. Release of
LDH from untreated BMDMs served as a negative control and this
amount was subtracted from the positive control and peptide-
treated groups. As shown in Fig. 2a, for all three MDP peptides, it
was observed that an increase of peptide concentration above 1 mM
abolished the MDP’s cytotoxicity. At first, this observation is quite
surprising as it is contrary to dose-dependent relationships between
concentration and cytotoxicity. Although the detailed molecular
mechanism is unknown, we hypothesized that at low peptide
concentrations, monomers/oligomers exist predominantly and
they have the ability to insert into lipid membranes and cause
membrane disruption and LDH leakage.
Such action is reminiscent of the working mechanism of
most natural and synthetic single chained AMPs against both
bacteria and mammalian cells. However, as peptide concen-
tration increases, monomers/oligomers undergo self-assembly
into supramolecular nanofibers. MDPs, having the charac-
teristic of amyloid-like peptides, are more likely to follow the
typical autocatalytic growth of nanofiber formation.8,10 Mono-
mers/oligomers will be quickly consumed and organized into
supramolecular nanofibers. MDP fibers are relatively short
(below 100 nm) due to the electrostatic repulsion so as to remain
soluble in aqueous buffer, whereas typical amyloid-like peptides
form elongated fibers on the order of at least micrometers in length
and eventually precipitate out of the solution. Reduced cytotoxicity
was mainly attributed to the formation of these supramolecular,
Scheme 1 Color-coded chemical structure of a MDP that can be designed to
contain variable numbers of lysine residues and (QL) repeating units for the
investigation of both molecular and supramolecular structure-dependent cyto-
toxicity and antimicrobial activity. Red: leucine; green: glutamine; grey: lysine.
Fig. 1 TEM images of MDPs that self-assembled into supramolecular
nanofibers. (a) WK2(QL)6K2 (b) WK3(QL)6K2 (c) K3W(QL)6K2. Peptide solution
was prepared in Tris buffer (pH = 7.4, 20 mM) with a final peptide concen-
tration at 100 mM. Scale bar: 50 nm.
Fig. 2 (a) Effect of different MDPs on the viability of the BMDMs. (b) Effect of
melittin on the viability of the BMDMs. (c) Quantitative analysis of the cytotoxic
effect of MDPs on the BMDMs. Total number of cells observed after treatment
of BMDMs with 1 mM and 20 mM of peptides were quantitated as compared to
the uninfected control. Results are shown as the mean  SEM. ***Po 0.001.
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short, soluble nanofibers which have been found to be more
membrane permeable3a and therefore less cytotoxic. In contrast
to the fiber-forming MDPs, as shown in Fig. 2b, melittin as a
monomeric AMP, is highly cytotoxic and exhibits a dose-
dependent effect. In Fig. 2c the effect of exposure to 1 and
20 mM MDP on the total number of cells per tissue culture well
is presented. In accord with the LDH release results, exposure
to 1 mM, but not 20 mM MDP resulted in a significant decrease
in cell numbers compared to untreated controls.
Recently, antimicrobial supramolecular assemblies have
been designed based on the self-assembly of terephthalamide core
bis-urea containing cationic polymers and small molecules.4a,11
Current work on the design of antimicrobial supramolecular
peptides echoes these previous efforts for the construction of
highly effective antimicrobial supramolecular biomaterials.
Successful design of antimicrobial peptides beyond the mole-
cular level will also complement conventional AMPs design and
provide unique opportunities for treating intracellular bacterial
infections, which is another topic being studied in our lab and
will be reported separately.
The primary goal of this work is to demonstrate the anti-
microbial effect of the designed supramolecularMDPs on bacterial
viability and understand the influence of various physical and
chemical parameters on antimicrobial efficiency. The antimicro-
bial activities of WK2(QL)6K2, WK3(QL)6K2, and K3W(QL)6K2 were
tested against both gram negative bacteria, Escherichia coli and
Pseudomonas aeruginosa and gram positive bacteria, Staphylococcus
epidermidis and S. aureus. Peptides were co-incubated with each
bacterial species for 18 h (for E. coli and P. aeruginosa) or 36 h (for
S. aureus and S. epidermidis) and the UV absorbance at 600 nmwas
measured for the calculation of minimum inhibitory concen-
tration (MIC) values. As shown in Table 1, based on the MIC
results, WK3(QL)6K2 was found to have the most effective anti-
microbial activity, followed by K3W(QL)6K2 and WK2(QL)6K2.
Different antimicrobial effects were also confirmed by a
bacterial killing efficiency study where 99% of gram negative
bacteria were killed by WK3(QL)6K2, 98% by K3W(QL)6K2, and
less than 40% by WK2(QL)6K2 (Fig. S4, ESI†). The same trend of
killing activity was observed with gram-positive bacteria. Such
order of activity inversely correlates with the peptides’ tendency
to form beta sheets and thus the stability of the supramolecular
nanofibers. We believe that charge density plays a minimal role
in the antimicrobial action of these supramolecular assemblies.
MDP-2 and 3 have the exact same residue composition and
charge density, yet they display dramatically different anti-
microbial activities. A parallel study in our lab showed that
D-amino acid substitution for the lysine residues on WK2(QL)6K2
slightly reduced beta sheet content and nanofiber integrity (data
not shown). However, the antimicrobial efficiency was dramatically
improved for the D-peptide although both D and L peptides contain
the same number of charged residues. Additionally, the residual
peptide monomer is not likely to contribute to the different
antimicrobial activities observed since the CACs are quite low.
More importantly, negligible amounts of monomers are expected
in solution due to the consumption of monomers/oligomers in the
process of autocatalytic growth of the nanofibers. Indeed, it is the
intermolecular interactions between MDP building blocks that
plays a key role in the membrane activity of these supramolecular
assemblies and directly influences both primary cell viability and
antimicrobial activity.
Scanning electron microscopy (SEM) was used to visualize
the morphological change in bacteria with the addition of
different MDPs. All three peptides were incubated with bacteria
for 1 h before SEM imaging. Fig. S5 (ESI†) shows themorphological
changes in E. coli and S. aureus when exposed to peptides. Both
WK3(QL)6K2 and K3W(QL)6K2 caused bacterial cell damage and
confirmed the mode of antimicrobial activity through membrane
disruption. WK2(QL)6K2, however, showed negligible membrane
disruption as compared to control.
A significant concern of peptides composed of natural amino
acids is their protease susceptibilities. Peptides consisting of non-
natural amino acids, such as D-amino acids,12 b-amino acids,2i,l a/g-
AA amino acids,2f,13 and peptoids14 have been successfully designed
and synthesized to solve the issue of protease stability, although the
cost of their production may be prohibitive for general widespread
use. More recently, peptide nanofilaments and nanobeacons were
shown to have different enzymatic degradation rates.15 Consistent
with this recent discovery, our results demonstrate that the supra-
molecular assembly can be used as another effective approach to
improve the protease susceptibilities of antimicrobial peptides
containing naturally occurring a-amino acids. As shown in Fig. 3,
peptides without enzymatic treatment were eluted as amajor singlet
atB17 min. The three MDPs showed differing proteolytic stability
upon incubation with two common enzymes, trypsin and chymo-
trypsin for 18 h and the degradation products of each peptide were
monitored by HPLC.
For WK2(QL)6K2, a larger fraction of materials remained
intact in the presence of these enzymes. With the addition of
a single lysine residue, WK3(QL)6K2 exhibited dramatically
Table 1 MIC results of WK2(QL)6K2, WK3(QL)6K2, and K3W(QL)6K2 against
E. coli, P. aeruginosa, S. aureus, and S. epidermidis showing sequence/
structure dependent antimicrobial activity
Peptide sequences
MIC (mM)
E. C. P. A. S. A. S. E.
WK2(QL)6K2 480 480 480 80
WK3(QL)6K2 20 20 10 5
K3W(QL)6K2 80 80 20 10
Fig. 3 Proteolytic stability of MDPs monitored by HPLC. (a) WK2(QL)6K2
(b) WK3(QL)6K2 (c) K3W(QL)6K2. Bottom trace: peptide without the addition
of enzymes; middle: trypsin; top: chymotrypsin.
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diminished stability as demonstrated by a HPLC peak shift upon
enzymatic treatment. However, the enzymatic stability was
retrieved for K3W(QL)6K2, which has a larger fraction of beta
sheets and therefore greater supramolecular stability. Quantitative
results of the percentage of degradation are summarized in Table
S1 (ESI†). The resistance to proteolytic degradation observed here
strongly correlates with the peptides’ ability to self-assemble into
supramolecular nanostructures. The refined nanostructures are
likely to create steric hindrance for the proteases to access the
active reaction sites thereby reducing degradation. Additionally, in
the presence of serum, MDP-1 and MDP-2 with higher beta sheet
contents are more stable than MDP-3 with reduced beta sheet
character (Fig. S6, ESI†). A summary of the molecular structures
and biological activities of MDP nanofibers was shown in Fig. S7
(ESI†). It can be envisioned that through co-assembly of different
sequenced MDPs, an ideal balance between supramolecular
nanostructure, protease stability, cytotoxicity, and antimicrobial
activity could be achieved.
In conclusion, supramolecular peptide assemblies have been
demonstrated to be a viable platform for the design and synthesis
of AMPs that can strike a balance between structure, stability,
cytotoxicity, and antimicrobial activity. Herein, we provided a new
paradigm for functional AMP design to enhance the effectiveness
of anti-infective treatments. Fundamental understanding of the
structure–activity correlation beyond the molecular level will push
forward the application of conventional AMPs in topical anti-
infective therapy. It will also engender enormous opportunities for
AMPs-based systemic antimicrobial treatments where both stabi-
lity and cytotoxicity have been significant concerns to date. In
addition, successful design of supramolecular AMPs will greatly
advance the development of suitable strategies for combating
intracellular microbial infection where the cell penetration activity
of AMPs plays a key role for effective treatments. Future work
should focus on models of intracellular bacterial infection using
these supramolecular peptide assemblies and related work has
been initiated in our lab.
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